Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis
Completed
Azidus Brasil
Phase 2/Phase 3
2008-07-01
The Psoriasis and a chronic dermatosis characterized by abnormal proliferation of cells
epithelial, vessel dilation and inflammation locally, which presents erythematous-scaly
lesions in various areas of the body, preferably in the scalp, region and religious joints as
elbows and knees. It occurs equally in both sexes and can appear at any age, and the mean age
for the onset of the disease and around 27.3 years.
The halobetasol propionate and an ultra-potent corticoid. Its chemical structure and similar
to the Clobetasol corticoid this, until then classified as the most potent corticoid used
worldwide in clinical practice. However, the molecular structure of Halobetasol gives it
increased its activity antiinflammatory and anti-proliferative.
The objective of this study is evaluating the efficacy and tolerability of the drug
Halobetasol propionate cream formulation as a treatment in patients with plaque psoriasis
mild to moderate, compared to the substance of similar power, Clobetasol propionate - Psorex
- Cream.
Randomized Study to Compare the Bioavailability of Two Halobetasol Propionate 0.05% Topical Ointments
Completed
Padagis LLC
2003-07-01
The purpose of this study was to compare the relative vasoconstrictive effects of test and
reference Halobetasol Propionate 0.05% Ointment in healthy, female subjects.
Randomized Study to Compare the Bioavailability of Two Halobetasol Propionate 0.05% Topical Ointments
Completed
Perrigo Company
2003-07-01
The purpose of this study was to compare the relative vasoconstrictive effects of test and
reference Halobetasol Propionate 0.05% Ointment in healthy, female subjects.
Randomized Study to Compare the Bioavailability of Three Halobetasol Propionate 0.05% Topical Creams
Completed
Padagis LLC
2004-01-01
The purpose of this study was to compare the relative vasoconstrictive effects of two test
and one reference Halobetasol Propionate 0.05% Cream in healthy, female subjects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
